Page 274 - Pagetit

INDEX

Buprenorphine, treatment of opioid dependence 82, 83
Bupropion, placebo in smoking studies 181

Candidate gene studies 128, 140–147
conflicting results 149–9 ?????
confounding issues 147–148
dopaminergic system 141–145
Cannabinoids 84–88, 108
adaptations to prolonged use 88
behavioural effects 85–6
CB1 receptor 86–87
mechanism of action 86–87
therapeutic potential 85
tolerance and withdrawal 87–88
Catechol-O-methyltransferase polymorphisms 144–145
Cathinone, khat (Catha edulis) 94
Caudate 23, 24
Cerebral cortex 22
Cerebral hemispheres 22–25
Chloride channels (see also Ion channels) 74
Cholecystokinin, interactions with dopamine 147
Clinical trials, ethical issues 210–211, 225–227
pharmacological treatments 225–227
conflicts of interests 226–227
distributive justice 217, 226
trial design 225
pharmacotherapy of prevention 211
Clozapine, schizophrenia 175–176
Co-morbidity 169–207
hypotheses 170–176
Cocaine 89–93, 108
adaptations to prolonged use 91
behavioural effects 89
dependence, and schizophrenia 174–175
dopamine levels in frontal cortex 178
mechanism of action 89–90
prevention studies, immunotherapy 229–231
reduction in use with antidepressants 182
tolerance and withdrawal 91
development of tolerance 54
treatment of dependence 92–93
vaccines 92–93
Coercion, legal, treatment 232–235
Cognition, defined 56

253

Index 253 19.1.2004, 11:52